(Q34084575)

English

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

0 references

author name string

Mark H Kirschbaum

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kenneth A Foon

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Paul Frankel

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Christopher Ruel

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Bernadette Pulone

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Joseph M Tuscano

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Edward M Newman

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

24 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2301-2304

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143479

5 July 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.877134

21 January 2018

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.877134

21 January 2018

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2013.877134

21 January 2018

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24369094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of prognostic factors in AML. Preface

1 reference

https://pubmed.ncbi.nlm.nih.gov/24369094

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/10428194.2013.877134

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34084575&oldid=1539607186"